Novavax, Inc. (NVAX)

Novavax, Inc. is a biotechnology company founded in 1987, focusing on the development and commercialization of innovative vaccines to prevent serious infectious diseases. Headquartered in Gaithersburg, Maryland, Novavax gained significant attention for its work on a COVID-19 vaccine, among other viral threats. As of 2023, John C. Jacobs serves as the company's President and CEO, guiding its mission to improve global health through cutting-edge vaccine technology. Known for its recombinant nanoparticle technology, Novavax emphasizes rigorous research and development processes to create safe and effective vaccines. The company has made notable strides in public health, especially throughout the COVID-19 pandemic. Their emphasis on innovation continues to contribute substantially to their growth and presence in the biotech industry. Keep an eye on their financial reports to see how they continue to navigate and expand in a competitive market.